FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091006069> ?p ?o ?g. }

• W3091006069 endingPage "3356" @default.
• W3091006069 startingPage "3346" @default.
• W3091006069 abstract "Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line treatments in patients with advanced/metastatic non‐small cell lung cancer (NSCLC). Methods We analyzed data of 2157 patients of the Czech TULUNG Registry of patients with advanced/metastatic NSCLC who received modern‐era treatments between 2011 and 2018. Patients treated with gefitinib, erlotinib, afatinib, bevacizumab (+ maintenance), pemetrexed (+ maintenance) as first‐line therapy were included in the study. A systematic literature search separately identified clinical trials suitable for calculation of comparator pooled OS and PFS for each regimen. For each subgroup, basic characteristics and survival data (Kaplan‐Meier estimates) are shown. We propose the “index of real‐life effectiveness” (IRE), a ratio of real‐life OS/PFS and comparator pooled OS/PFS. Univariate and multivariate logistic regression identified factors were associated with longer OS (ie, IRE>1.1). Results Survival analysis showed median OS of 23 months for erlotinib, 29.3 months for afatinib, 19.6 months for gefitinib, 12.2 months for pemetrexed, 17.5 months for pemetrexed maintenance, 15.8 months for bevacizumab and 15.8 months for bevacizumab maintenance. Calculated IREs for OS for the regimens were: erlotinib 1.013, afatinib 1.184, gefitinib 0.736, pemetrexed 1.188, pemetrexed maintenance 1.294, bevacizumab 1.178, and bevacizumab maintenance 1.189. Multivariate regression analysis showed that these factors were associated with longer OS: lower PS for afatinib; lower PS, absence of adverse events and female sex for bevacizumab; and lower PS and female sex for pemetrexed. Conclusions This study clearly demonstrated that real‐life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems, and comparison between TULUNG data and pooled survival data from trials showed higher real‐life effectiveness for most of the studied first‐line regimens. Lower ECOG PS, younger age, female sex and adverse events were associated with longer survival in most regimens. Key points Significant findings of the study Comparison between TULUNG data and pooled survival data from trials showed higher real‐life effectiveness for most of the studied first‐line regimens; for most regimens, lower ECOG PS, younger age, female sex and adverse events were associated with longer survival. What this study adds Real‐life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems." @default.
• W3091006069 created "2020-10-08" @default.
• W3091006069 creator A5004795208 @default.
• W3091006069 creator A5007665505 @default.
• W3091006069 creator A5011654804 @default.
• W3091006069 creator A5017770548 @default.
• W3091006069 creator A5018473625 @default.
• W3091006069 creator A5027486559 @default.
• W3091006069 creator A5040658064 @default.
• W3091006069 creator A5073240267 @default.
• W3091006069 creator A5076639897 @default.
• W3091006069 creator A5078858541 @default.
• W3091006069 creator A5080367058 @default.
• W3091006069 creator A5086513368 @default.
• W3091006069 creator A5089400207 @default.
• W3091006069 creator A5091059437 @default.
• W3091006069 date "2020-10-05" @default.
• W3091006069 modified "2023-10-17" @default.
• W3091006069 title "Real‐life effectiveness of first‐line anticancer treatments in stage <scp>IIIB</scp> / <scp>IV NSCLC</scp> patients: Data from the <scp>C</scp> zech <scp>TULUNG R</scp> egistry" @default.
• W3091006069 cites W1933163981 @default.
• W3091006069 cites W1964370859 @default.
• W3091006069 cites W2019607817 @default.
• W3091006069 cites W2040253672 @default.
• W3091006069 cites W2099725888 @default.
• W3091006069 cites W2101610090 @default.
• W3091006069 cites W2106664438 @default.
• W3091006069 cites W2111662961 @default.
• W3091006069 cites W2112621029 @default.
• W3091006069 cites W2115330744 @default.
• W3091006069 cites W2120676861 @default.
• W3091006069 cites W2129360604 @default.
• W3091006069 cites W2130357378 @default.
• W3091006069 cites W2132157071 @default.
• W3091006069 cites W2133149289 @default.
• W3091006069 cites W2135140316 @default.
• W3091006069 cites W2140742135 @default.
• W3091006069 cites W2145835533 @default.
• W3091006069 cites W2148367564 @default.
• W3091006069 cites W2149733252 @default.
• W3091006069 cites W2154662831 @default.
• W3091006069 cites W2156438240 @default.
• W3091006069 cites W2160982674 @default.
• W3091006069 cites W2166084034 @default.
• W3091006069 cites W2167191456 @default.
• W3091006069 cites W2171139285 @default.
• W3091006069 cites W2210071992 @default.
• W3091006069 cites W2339311613 @default.
• W3091006069 cites W2343576357 @default.
• W3091006069 cites W2343928958 @default.
• W3091006069 cites W2515618649 @default.
• W3091006069 cites W2572035171 @default.
• W3091006069 cites W2608495247 @default.
• W3091006069 cites W2615006430 @default.
• W3091006069 cites W2616160160 @default.
• W3091006069 cites W2619919786 @default.
• W3091006069 cites W2755379475 @default.
• W3091006069 cites W2760639821 @default.
• W3091006069 cites W2766146632 @default.
• W3091006069 cites W2784243589 @default.
• W3091006069 cites W2803647087 @default.
• W3091006069 cites W2806325305 @default.
• W3091006069 cites W2808643725 @default.
• W3091006069 cites W2902270791 @default.
• W3091006069 cites W2940905346 @default.
• W3091006069 cites W2944167983 @default.
• W3091006069 cites W2964616479 @default.
• W3091006069 cites W2966170824 @default.
• W3091006069 cites W2975758168 @default.
• W3091006069 cites W2978677918 @default.
• W3091006069 cites W2987053327 @default.
• W3091006069 cites W2998415311 @default.
• W3091006069 doi "https://doi.org/10.1111/1759-7714.13679" @default.
• W3091006069 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7606010" @default.
• W3091006069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33016001" @default.
• W3091006069 hasPublicationYear "2020" @default.
• W3091006069 type Work @default.
• W3091006069 sameAs 3091006069 @default.
• W3091006069 citedByCount "6" @default.
• W3091006069 countsByYear W30910060692021 @default.
• W3091006069 countsByYear W30910060692022 @default.
• W3091006069 countsByYear W30910060692023 @default.
• W3091006069 crossrefType "journal-article" @default.
• W3091006069 hasAuthorship W3091006069A5004795208 @default.
• W3091006069 hasAuthorship W3091006069A5007665505 @default.
• W3091006069 hasAuthorship W3091006069A5011654804 @default.
• W3091006069 hasAuthorship W3091006069A5017770548 @default.
• W3091006069 hasAuthorship W3091006069A5018473625 @default.
• W3091006069 hasAuthorship W3091006069A5027486559 @default.
• W3091006069 hasAuthorship W3091006069A5040658064 @default.
• W3091006069 hasAuthorship W3091006069A5073240267 @default.
• W3091006069 hasAuthorship W3091006069A5076639897 @default.
• W3091006069 hasAuthorship W3091006069A5078858541 @default.
• W3091006069 hasAuthorship W3091006069A5080367058 @default.
• W3091006069 hasAuthorship W3091006069A5086513368 @default.
• W3091006069 hasAuthorship W3091006069A5089400207 @default.
• W3091006069 hasAuthorship W3091006069A5091059437 @default.
• W3091006069 hasBestOaLocation W30910060691 @default.
• W3091006069 hasConcept C121608353 @default.

• next